Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
In biological research, especially in areas such a
The Nobel Prize in Physiology or Medicine awarded
India is one of the largest centers of global phar
By the end of 2025, the pharma, laboratory, and an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micro
Pfizer Inc has decided to price its COVID-19 vaccine candidate, BNT162b2 COVID-19, on the basis of the GDP of the country. The Chief Executive Officer of the American pharmaceutical company, Albert Bourla, has said the company will have tiered pricing to its middle-income nations, including India.
The COVID-19 vaccine developed by Pfizer and BioNTech was initially approved by Britain on December 2. A week after the approval, the initial shot was administered on December 8 to Margaret Keenan, a 90-year-old girl from Northern Ireland. An early riser, Keenan received the jab in her local hospital in Coventry, central England, a week before she turns 91.
Pfizer has applied for emergency use authorisation of its coronavirus vaccine in India. The firm is the first to do so in a country with the world’s second-highest variety of infections.
The US company approached Indian authorities on December 5, VK Paul, who’s advising the government on COVID-19 matters reportedly said.
India’s drugs regulator normally takes up to 90 days to decide on such applications but a decision on Pfizer’s vaccine could come much faster than that, Paul said.
The Pfizer shot needs to be kept at minus 70 degrees Celsius (-94 F) or below, temperatures that industry experts say many cold storage facilities in India will find it tough to keep.
India has reported more than 97.35 lakh COVID-19 instances, the planet’s second-highest following the United States, with more than 1.41 lakh deaths, according to the union health ministry’s data released on December 9.
